Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features

Suyan Li, Yota Uno, Uwe Rudolph, Johanna Cobb, Jing Liu, Thea Anderson, Deborah Levy, Darrick T. Balu, Joseph T. Coyle

Research output: Contribution to journalArticle

Abstract

D-Serine is a co-agonist at forebrain N-methyl-D-aspartate receptors (NMDAR) and is synthesized by serine racemase (SR). Although D-serine and SR were originally reported to be localized to glia, recent studies have provided compelling evidence that under healthy physiologic conditions both are localized primarily in neurons. However, in pathologic conditions, reactive astrocytes can also express SR and synthesize D-serine. Since cultured astrocytes exhibit features of reactive astrocytes, we have characterized D-serine synthesis and the expression of enzymes involved in its disposition in primary glial cultures. The levels of SR were quite low early in culture and increased markedly in all astrocytes with the duration in vitro. The concentration of D-serine in the culture medium increased in parallel with SR expression in the astrocytes. Microglia, identified by robust expression of Iba1, did not express SR. While the levels of glial fibrillary acidic protein (GFAP), glycine decarboxylase (GLDC) and phosphoglycerate dehydrogenase (PHGDH), the initial enzyme in the pathway converting glycine to L-serine, remained constant in culture, the expression of lipocalin-2, a marker for pan-reactive astrocytes, increased several-fold. The cultured astrocytes also expressed Complement-3a, a marker for a subpopulation of reactive astrocytes (A1). Astrocytes grown from mice with a copy number variant associated with psychosis, which have four copies of the GLDC gene, showed a more rapid production of D-serine and a reduction in glycine in the culture medium. These results substantiate the conclusion that A1 reactive astrocytes express SR and release D-serine under pathologic conditions, which may contribute to their neurotoxic effects by activating extra-synaptic NMDARs.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalBiochemical Pharmacology
Volume151
DOIs
StatePublished - May 2018
Externally publishedYes

Fingerprint

Astrocytes
Serine
Glycine Dehydrogenase (Decarboxylating)
Glycine Dehydrogenase
Neuroglia
Glycine
Culture Media
Phosphoglycerate Dehydrogenase
Complement C3a
serine racemase
Lipocalins
Glial Fibrillary Acidic Protein
Microglia
Enzymes
Prosencephalon
N-Methyl-D-Aspartate Receptors
Psychotic Disorders
Neurons
Genes

Keywords

  • Astrocytes
  • Copy number variant
  • D-Serine
  • Glycine decarboxylase
  • N-Methyl-D-aspartate receptor
  • Serine racemase

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features. / Li, Suyan; Uno, Yota; Rudolph, Uwe; Cobb, Johanna; Liu, Jing; Anderson, Thea; Levy, Deborah; Balu, Darrick T.; Coyle, Joseph T.

In: Biochemical Pharmacology, Vol. 151, 05.2018, p. 245-251.

Research output: Contribution to journalArticle

Li, Suyan ; Uno, Yota ; Rudolph, Uwe ; Cobb, Johanna ; Liu, Jing ; Anderson, Thea ; Levy, Deborah ; Balu, Darrick T. ; Coyle, Joseph T. / Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features. In: Biochemical Pharmacology. 2018 ; Vol. 151. pp. 245-251.
@article{46f77a97885445788baaa1513f30cb9a,
title = "Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features",
abstract = "D-Serine is a co-agonist at forebrain N-methyl-D-aspartate receptors (NMDAR) and is synthesized by serine racemase (SR). Although D-serine and SR were originally reported to be localized to glia, recent studies have provided compelling evidence that under healthy physiologic conditions both are localized primarily in neurons. However, in pathologic conditions, reactive astrocytes can also express SR and synthesize D-serine. Since cultured astrocytes exhibit features of reactive astrocytes, we have characterized D-serine synthesis and the expression of enzymes involved in its disposition in primary glial cultures. The levels of SR were quite low early in culture and increased markedly in all astrocytes with the duration in vitro. The concentration of D-serine in the culture medium increased in parallel with SR expression in the astrocytes. Microglia, identified by robust expression of Iba1, did not express SR. While the levels of glial fibrillary acidic protein (GFAP), glycine decarboxylase (GLDC) and phosphoglycerate dehydrogenase (PHGDH), the initial enzyme in the pathway converting glycine to L-serine, remained constant in culture, the expression of lipocalin-2, a marker for pan-reactive astrocytes, increased several-fold. The cultured astrocytes also expressed Complement-3a, a marker for a subpopulation of reactive astrocytes (A1). Astrocytes grown from mice with a copy number variant associated with psychosis, which have four copies of the GLDC gene, showed a more rapid production of D-serine and a reduction in glycine in the culture medium. These results substantiate the conclusion that A1 reactive astrocytes express SR and release D-serine under pathologic conditions, which may contribute to their neurotoxic effects by activating extra-synaptic NMDARs.",
keywords = "Astrocytes, Copy number variant, D-Serine, Glycine decarboxylase, N-Methyl-D-aspartate receptor, Serine racemase",
author = "Suyan Li and Yota Uno and Uwe Rudolph and Johanna Cobb and Jing Liu and Thea Anderson and Deborah Levy and Balu, {Darrick T.} and Coyle, {Joseph T.}",
year = "2018",
month = "5",
doi = "10.1016/j.bcp.2017.12.023",
language = "English (US)",
volume = "151",
pages = "245--251",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features

AU - Li, Suyan

AU - Uno, Yota

AU - Rudolph, Uwe

AU - Cobb, Johanna

AU - Liu, Jing

AU - Anderson, Thea

AU - Levy, Deborah

AU - Balu, Darrick T.

AU - Coyle, Joseph T.

PY - 2018/5

Y1 - 2018/5

N2 - D-Serine is a co-agonist at forebrain N-methyl-D-aspartate receptors (NMDAR) and is synthesized by serine racemase (SR). Although D-serine and SR were originally reported to be localized to glia, recent studies have provided compelling evidence that under healthy physiologic conditions both are localized primarily in neurons. However, in pathologic conditions, reactive astrocytes can also express SR and synthesize D-serine. Since cultured astrocytes exhibit features of reactive astrocytes, we have characterized D-serine synthesis and the expression of enzymes involved in its disposition in primary glial cultures. The levels of SR were quite low early in culture and increased markedly in all astrocytes with the duration in vitro. The concentration of D-serine in the culture medium increased in parallel with SR expression in the astrocytes. Microglia, identified by robust expression of Iba1, did not express SR. While the levels of glial fibrillary acidic protein (GFAP), glycine decarboxylase (GLDC) and phosphoglycerate dehydrogenase (PHGDH), the initial enzyme in the pathway converting glycine to L-serine, remained constant in culture, the expression of lipocalin-2, a marker for pan-reactive astrocytes, increased several-fold. The cultured astrocytes also expressed Complement-3a, a marker for a subpopulation of reactive astrocytes (A1). Astrocytes grown from mice with a copy number variant associated with psychosis, which have four copies of the GLDC gene, showed a more rapid production of D-serine and a reduction in glycine in the culture medium. These results substantiate the conclusion that A1 reactive astrocytes express SR and release D-serine under pathologic conditions, which may contribute to their neurotoxic effects by activating extra-synaptic NMDARs.

AB - D-Serine is a co-agonist at forebrain N-methyl-D-aspartate receptors (NMDAR) and is synthesized by serine racemase (SR). Although D-serine and SR were originally reported to be localized to glia, recent studies have provided compelling evidence that under healthy physiologic conditions both are localized primarily in neurons. However, in pathologic conditions, reactive astrocytes can also express SR and synthesize D-serine. Since cultured astrocytes exhibit features of reactive astrocytes, we have characterized D-serine synthesis and the expression of enzymes involved in its disposition in primary glial cultures. The levels of SR were quite low early in culture and increased markedly in all astrocytes with the duration in vitro. The concentration of D-serine in the culture medium increased in parallel with SR expression in the astrocytes. Microglia, identified by robust expression of Iba1, did not express SR. While the levels of glial fibrillary acidic protein (GFAP), glycine decarboxylase (GLDC) and phosphoglycerate dehydrogenase (PHGDH), the initial enzyme in the pathway converting glycine to L-serine, remained constant in culture, the expression of lipocalin-2, a marker for pan-reactive astrocytes, increased several-fold. The cultured astrocytes also expressed Complement-3a, a marker for a subpopulation of reactive astrocytes (A1). Astrocytes grown from mice with a copy number variant associated with psychosis, which have four copies of the GLDC gene, showed a more rapid production of D-serine and a reduction in glycine in the culture medium. These results substantiate the conclusion that A1 reactive astrocytes express SR and release D-serine under pathologic conditions, which may contribute to their neurotoxic effects by activating extra-synaptic NMDARs.

KW - Astrocytes

KW - Copy number variant

KW - D-Serine

KW - Glycine decarboxylase

KW - N-Methyl-D-aspartate receptor

KW - Serine racemase

UR - http://www.scopus.com/inward/record.url?scp=85040231764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040231764&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2017.12.023

DO - 10.1016/j.bcp.2017.12.023

M3 - Article

C2 - 29305854

AN - SCOPUS:85040231764

VL - 151

SP - 245

EP - 251

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -